+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade



Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade



Supportive Care in Cancer 12(1): 53-57



To evaluate the effectiveness and side effects of intrapericardial administration of cisplatin in prevention of recurrent malignant pericardial effusion. Forty-six patients (33 men, 13 women; mean age 55.6+/-10.5 years) entered this study. The diagnosis of malignancy was based upon histological examination of samples from primary tumor. The majority of patients suffered from a neoplasm localized in the thorax (41 out of 46 patients; 89%). In 35 cases, pericardiocentesis, and in 11 cases, video-assisted thoracoscopic surgery (VATS) of pericardium was performed. Malignant etiology of pericardial fluid was confirmed by cytological examination, histology being obtained by VATS pericardial biopsy or by echocardiography (ECG). If daily drainage of pericardial fluid observed during 5-7 days exceeded 50 ml, cisplatin was instilled according to one of three regimens: (1) 10 mg of cisplatin dissolved in 20 ml of normal saline administered over 5 min during 5 consecutive days directly into the pericardial space (39 patients); (2) 50 mg of cisplatin dissolved in 100 ml of normal saline administered during 30 min (six patients); and (3) 20 mg of cisplatin dissolved in 40 ml of normal saline administered over 10 min during 5 consecutive days (one patient). Treatment was considered as successful when recurrence of symptoms of large pericardial effusion was not observed in ECG and other interventions directed to the pericardium were not required. Efficacy of investigated treatment was assessed also in the group of patients with survival longer than 30 days. Safety of treatment was assessed in the whole group of patients. Because of advanced malignancy eight out of 46 patients (17.4%) survived less than 30 days. Thirty-eight out of 46 cases (82.6%) survived more than 30 days. Positive effect of intrapericardial treatment with cisplatin was achieved in 43 out of 46 patients (93.5%) in the entire investigated group and in 35 out of 38 patients (92%) who survived more than 30 days. In the subgroup of patients with non-small cell lung cancer (NSCLC) and survival longer than 30 days, high efficacy was documented (29 out of 31 cases; 93.5%). Median survival time in the group of 38 patients who survived more than 30 days was 102.5 days. Atrial fibrillation due to cisplatin administration was observed in seven out of 46 patients (15.2%). Sclerosis of the pericardial space without symptoms of constriction occurred in five out of 46 cases (10.9%). Cisplatin administered directly into the pericardial space is a very effective and relatively safe method of treatment of recurrent malignant pericardial effusion, especially in the course of NSCLC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 048997135

Download citation: RISBibTeXText

PMID: 14505155

DOI: 10.1007/s00520-003-0533-x


Related references

Evaluation of intrapericardial cisplatin administration in cases of recurrent malignant pericardial effusion and cardiac tamponade. Pneumonologia i Alergologia Polska 64 Suppl 2: 180-186, 1996

Intrapericardial instillation of mitomycin C in recurrent cardiac tamponade due to malignant pericardial effusion. Clinical Oncology ) 18(6): 506, 2006

Intrapericardial tetracycline for the management of cardiac tamponade secondary to malignant pericardial effusion. New England Journal of Medicine 299(20): 1113-1114, 1978

Intrapericardial bleomycin for the management of cardiac tamponade secondary to malignant pericardial effusion. British Heart Journal 63(1): 61-62, 1990

Prolonged Drainage and Intrapericardial Bleomycin Administration for Cardiac Tamponade Secondary to Cancer-Related Pericardial Effusion. Medicine 95(15): E3273, 2016

Intrapericardial cisplatin administration after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade. Hellenic Journal of Cardiology 46(5): 324-329, 2005

Intrapericardial cisplatin in malignant pericardial effusion. European Journal of Cancer 27(SUPPL 3): S57, 1991

Pericardial effusion and cardiac tamponade caused by intrapericardial granulation tissue in a dog. Journal of Veterinary Emergency and Critical Care 19(2): 187-192, 2009

Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion. Journal Of Cancer Research & Clinical Oncology. 120(7): 434-436, 1994

A case of pericardial tamponade caused by recurrent breast cancer treated with intrapericardial and intrapleural infusion of cisplatin (CDDP). Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(8): 1133-1136, 2006

Pericardiocentesis with cisplatin for malignant pericardial effusion and tamponade. World Journal of Gastroenterology 16(6): 740-744, 2010

Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion in the course of the lung cancer. Lung Cancer 16(2-3): 215-222, 1997

Laparoscopic transabdominal pericardial window: new standard in the treatment of recurrent pericardial effusion complicated by cardiac tamponade. Surgical Endoscopy 16(5): 859-863, 2002

Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. Journal of Thoracic and Cardiovascular Surgery 112(3): 637-643, 1996

Intrapericardial Cisplatin Instillation in Recurrent Postinfarction Cardiac Tamponade. Journal of Cardiothoracic and Vascular Anesthesia 32(1): 458-460, 2017